Background and aims The aims of this study were, in people in treatment for drug use in Funen, Denmark, to: (1) assess
INTRODUCTION
The World Health Organization (WHO) Global Health Sector strategy on viral hepatitis states that the cascade of care begins with to what extent the population in need of an intervention is covered by it [1] . This implies that when evaluating hepatitis C virus (HCV) in any population, factors within the population that might affect coverage of an ongoing or planned intervention is of importance, especially if the population is diverse and prone to change over time. Although often referred to as a unity, people who use drugs (PWUD) are a heterogeneous population, and includes individuals at both high and low risk of acquiring HCV. Among PWUD, people who inject drugs (PWID) have a well-documented risk for HCV infection [2] [3] [4] . A recent systematic review reported a prevalence of HCV exposure [antibody-positive (anti-HCV+)] of 53.2% (48.4-57.9) among PWID in western Europe [5] . The risk of infection in PWID also depends on access to harm reduction, such as opiate substitution therapy (OST) and needle and syringe programmes (NSP) and the prevalence of infection in the local PWID community [6, 7] . The risk for HCV in people with non-injecting drug use is lower, but less well described. Sharing snorting straws and engagement in high-risk sexual practices have been identified as risk factors [8] [9] [10] . The heterogeneity of the population is likely to reflect upon test uptake [11] . Drug treatment programmes including OST can engage PWUD in testing, but it is of value to characterize the untested populations to assess coverage and guide future efforts [12] . Better data on the epidemiology of HCV in PWUD have been identified as a research priority and are essential for strategies on HCV prevention, test and treatment [13] . Registry-based studies might provide information on test coverage and the risk of HCV in current or former PWUD, including those no longer connected to treatment. The primary aim of this study was to estimate: (1) test uptake; and (2) the prevalence of HCV infection in people ever engaged in drug treatment. Secondary aims were to identify predictors for (3) test and (4) infection; and to (5) characterize changes over time in drug use, testing (including time from risk to test) and HCV infection.
METHOD

Design
This was a registry-based cohort study utilizing registry linkage between the Danish National Registry for Drug Users in Treatment (NRDT), the regional laboratory registry and the Danish Death Certificate Registry. All people with legal residency in Denmark have a unique 10-digit personal identification number (PIN) used for registry linkage.
There is no complete national test registry for HCV in Denmark, but restricting the cohort to the region of Funen, where complete laboratory data were available, allowed us to estimate test uptake and prevalence. The cohort [the ODense Drug user-HEPatitis cohort (ODD-HEP)] was derived from the NRDT and identified individuals ever in drug treatment in the Funen region. The region has been served exclusively by the same hepatitis laboratory since 1980 and electronic records were available. Data on all drug treatment episodes in the cohort throughout the country were included to obtain date of first entry into the registry and life-time risk behaviour. Data received from the NDRT were updated to 1 October 2015. Blood test results to 1 July 2016 were included to allow for 9 months of testing postentry. Mortality data were available to 31 December 2014.
Setting
The Funen region comprised 385 502 people aged 15-79 years in 2015 [14] . The region has publicly funded drug treatment at centres in the six major cities. The centres offer different kinds of out-patient treatment, including OST (mainly buprenorphine and methadone), with the centre in the largest city (Odense) also providing heroin-assisted therapy. In addition, individual or group therapy as well as medical treatment for non-opiate withdrawal symptoms are provided. Centres are staffed by addiction specialist doctors, nurses and people trained in various forms of therapy. Collaboration and liaison with the national health services and local social services are an integrated part of what the centres provide. Hepatitis testing is voluntary, but the centres are obliged to offer referral for testing. On-site testing for blood-borne infections, hepatitis consultation if infected and care by an infectious disease physician on a regular basis has been offered at the two largest centres since 2007 (outreach centres).
The Danish Registry on Drug Users in Treatment (NRDT)
The NRDT was formed in 1996. Reporting is mandatory for all publicly funded providers and linked to reimbursement. It contains detailed information on current and former drug use, injecting and treatment provided (type of OST/non-OST). Data are obtained by structured interviews following a standardized form. The information is collected initially at the initiation of each treatment episode and reported by the treatment centre to the registry. Demographic data on living conditions, source of income and education are also reported. Data were entered retrospectively for some clients, so the treatment start might be prior to 1996. In 2007 the system moved to a new platform, resulting in some double entries and breaches in data limiting the validity and quality of data regarding length of each treatment episode, and time in treatment is therefore not included in this analysis. The main variables derived from NRDT were basic demographics, date of first entry, history of OST, reported injecting, age at first injection, main drug used at first entry and ever drug use.
The Danish Death Certificate Registry
This registry comprises cause(s) of death for all people with a Danish PIN since 1970. It is updated yearly with a 1-year delay (to validate data). The data received on the cohort were updated to 31 December 2014. 
Measures
Test uptake and infection status
Test uptake for HCV was based on a recorded test in the laboratory registry for either anti-HCV or HCV-RNA. Participants were classified as being exposed to HCV if either anti-HCV+ or HCV-RNA+ and as having chronic HCV infection if the most recent HCV-RNA test was positive. In the estimate of 'time to test' and 'time to infection', only those initiating treatment in the region and had tested anti-HCV+ at some point were included to target those actually exposed and eliminate bias from being tested elsewhere at earlier treatment episodes.
Drug use and risk groups for infection
For comparative analysis, two groups were formed based on an assumed a priori risk of hepatitis C infection. Highrisk drug use was defined as either having ever received OST (methadone, buprenorphine, legal heroin or other OST) or ever reporting injecting. Including OST recipients with no disclosed injection in the high-risk population was mainly to overcome any bias introduced by nondisclosed injecting, as used in other registry-based studies [15] . Reported use of central stimulants (cocaine, amphetamines and derivatives) or opiates was categorized as use of 'hard drugs'.
Permission
The study was approved by the Danish Data Protection Agency (FSEID-00001805).
Data analysis
All data were anonymized prior to merging and analysis in Stata version 15. High-and low-risk groups were compared on binary outcomes using the χ 2 test and on continuous outcomes using the Mann-Whitney U-test, as all continuous variables were of non-normal distribution. Multiple logistic regressions reporting ORs for being tested and for having HCV included age, years since entry into treatment, gender, migrant status, unstable housing, ever in an outreach centre, ever on OST and ever injecting as covariates of interest. As data on migrant status and housing had many missing values, missing was included as a factor variable in the univariate analysis. Years since first treatment episode (observation stopped at death or 1 October 2015) and age were used to adjust for time in drug use and treatment, as it could not be established from the NRDT. Tests for trend in change in drug use at entry and HCV test exposure and prevalence by birth cohort and year of entry were performed using the nonparametric trend test in Stata nptrend (an extension of the Wilcoxon rank-sum test).
RESULTS
Population and risk behaviour
As of 1 October 2015, there were 5483 people with a valid PIN in the NRDT with at least one treatment episode in Funen (62 entries excluded due to invalid PIN). The high-risk group constituted 50% of the cohort; they were older when entering and more likely to be in treatment at the end of follow-up (Table 1) , and were more likely to be migrants/of migrant descent and have unstable housing. Eleven per cent of the high-risk group had not disclosed injecting. In the total cohort, 90% had their first and 87% their latest treatment in the region.
The number of first-time entries was stable over time; however, opiate use at entry changed significantly, showing an absolute and relative decrease (test for trend P < 0.01) ( Table 2 ). In participants with opiates as the main drug at entry (n = 1552), 80.2% eventually received OST. In participants not stating opiates or no information at entry, 15.3% later went onto OST.
There was a strong decline in reported injecting and receiving OST by year of entry ( 
Test uptake
Cumulative test uptake for HCV was significantly higher in the high-risk group (Table 3) and increased by birth cohort (Supporting information, Fig. S2 ). In the untested population, 85.7% of low-and 63.5% of high-risk individuals were no longer in treatment (nation-wide) at the end of follow-up. As of 1 October 2015, there were 965 individuals classified as at high risk of infection who were still in the region and in treatment; 11% of these had never been tested, and of those known to be anti-HCV negative (n = 324) only 33% had been re-tested within the last 18 months of the study.
Using multiple logistic regression, age, time since first treatment episode, female sex, ever in hepatitis outreach clinic, injecting and ever receiving OST were all associated with increased odds for testing when including the complete population (dead and alive) ( Table 4) .
Prevalence of HCV exposure and infection
The prevalence of ever testing positive for anti-HCV or HCV-RNA was 45% (n = 1361). Among anti-HCV+ individuals, 96% had been tested for HCV-RNA and 74% (1024 of Unstable more likely to be tested in univariate. NS = not significant; OST = opiate substitution therapy; CI = confidence interval. 1303) were positive for HCV-RNA (ever), with 291 (29%) having cleared (or been treated for) the infection at the latest test, giving a chronic/exposed ratio of 56%.
Median age at first positive HCV-RNA test in patients with chronic HCV infection at the end of follow-up was 35 years (IQR = 28-42) with no gender difference. For those 85 individuals diagnosed with chronic hepatitis C in 2010-16 the median age was 39 years (IQR = 32-46). Of the total of 531 individuals (median age = 45, IQR = 40-53) with chronic HCV infection alive as of 31 December 2014, 69% were still in treatment at the end of follow-up. Figure 2 illustrates the cumulative test, exposure and chronic HCV status in the high-risk group by year of entry. There was a significant decrease in the fraction with HCV (chronic and exposure) by year of entry. Test uptake was low (< 50%) in recent-year entrants. Data were also analysed excluding the deceased, but this did not alter the relative test and prevalence results.
In multiple logistic regression for predictors for chronic HCV infection, injecting was dominant [OR = 6.7 (4.7-9.6), P < 0.01], followed by history of OST [OR = 1.8 (1.4-2.3), P < 0.01] in age, gender and years since first treatment adjusted model (details not shown).
Observed differences within the high-risk group alive were that, in the younger birth cohorts, both tests, re-test if negative, infection and retention in care was highly dependent on receiving OST (Table 5) .
In people reporting ever injecting and alive as of end 2014, test uptake, HCV exposure and chronic HCV infection prevalence was 77, 62 and 33%, respectively. For those still in treatment, numbers were 86, 70 and 35%. Corresponding numbers for people ever on OST but without disclosed injecting showed the same test rate (77%), but a lower prevalence of exposure (15%) and chronic infection (8%).
Time to test
In a subgroup of 681 anti-HCV+ individuals having their first treatment episode in the region and available age at first injection, median time from first injection to test, first anti-HCV+ test and first HCV-RNA+ test was 6.5 (IQR = 2.3-13.6), 8.1 (IQR = 4.0-14.9) and 10.1 (IQR = 5.2-18.2) years, respectively. This decreased by birth cohort, with time to first test from first injection being 4.3 years (1.6-7.6) in people born after 1966 compared to 14.4 years (7.4-22.0) if born prior to 1966 (test for trend P < 0.001, Supporting information, Fig. S3 ). Absolute numbers of first-time testers for anti-HCV varied over time, coinciding with hepatitis projects in the region, but fraction of 'first-in-person' test showing exposure in the high-risk group decreased from 62% of those tested in 1996 to 19% in 2015 (test for trend P < 0.001, Supporting information, Fig. S4 ).
DISCUSSION
In this large cohort of people ever connected to drug treatment we found a hepatitis C test uptake of 55% and a prevalence of chronic infection of 21%. Hepatitis C was found mainly in people ever on OST or with a history of injecting. Test uptake was highly dependent on having ever received OST, and the majority of those with chronic HCV infection were still connected to drug treatment. The study has several limitations. We used a life-time risk classification, and results must be interpreted in that context. Additionally, the data on death were only updated until end 2014 and we thus slightly overestimated the population alive.
The cohort had a similar test uptake to a national study in 2007, and considering that testing people in drug treatment has been a priority in the region for 20 years, the finding is disappointing. However, we found the prevalence of chronic HCV infection to be substantially lower (21.2 versus 44.5%) than in 2007 [16] . These findings are largely explained by the change in the population connected to drug treatment. We found a significant decrease in first-time entrants stating opiate use as their main drug, and fewer than 20% of new entrants in the past 5 years had ever injected. Looking only at high-risk individuals alive at the end of follow-up, 79% were tested and 31% were HCV-RNA positive at the latest test.
The main determinant for being tested in this cohort was having ever received OST and secondly, a history of injecting drug use. Females had increased odds of testing, and this might reflect differences in health-seeking behaviour [17] . That OST programmes can engage PWUD in testing has been documented in several studies [18] . Outreach test interventions can, as we also found, increase test uptake regardless of testing method [12] , but the observed change in drug use in our cohort makes a focus on testing in non-OST injectors warranted. A limitation of this study is its reliance on regional testing data and as 13% of the cohort had their last treatment in a different region, test uptake is probably underestimated.
The defined a priori risk groups estimated the observed risk relatively accurately. We had defined high risk as either disclosing injecting or being on OST instead of PWID only as high risk. This can be debated, and people on OST without disclosed injection had a lower exposure to infection (18%) than those with (63%). The high exposure in the non-injecting OST population could reflect lack of disclosure or suboptimal reporting by centres, but remains speculative in this design. The chronic HCV infection prevalence in people considered at low risk for infection was 1.2% (alive population), which is higher than in the general adult Danish population (0.4%) and dependent on age, as almost no exposure was found in low-risk users born after 1976. In Denmark the use of central stimulants such as cocaine is relatively common, with 10% of the 15-25-year-olds reporting ever use [19, 20] . Infected blood can be recovered from snorting straws, and sharing these is common [21] . Cohort studies of HCV-infected non-injecting cocaine users [8] , men who have sex with men [22, 23] and prison inmates [24] have found snorting to be a risk factor for HCV exposure, but others have not [10, 25] . Our finding of low HCV prevalence in people not on OST/injecting use does not support sharing snorting straws as a major risk for HCV transmission.
There are no recent national data on HCV prevalence in Denmark for PWUD in drug treatment, but some data have been reported for PWID. According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2017 report, 52.5% of the PWID population in current drug treatment were anti-HCV-positive (based on 2008 data) [26] . We found an exposure in PWID of 70% among those in current treatment. This discrepancy can have several reasons, but regional differences and under-reporting in the national data is a probable cause.
In the high-risk population, we found a decline in HCV prevalence by birth year cohort and year of entry into treatment. Increased OST coverage and needle/syringe provision, including supervised injection rooms during the study period, are plausible causes of these results, but remains speculative. We found a decline in both absolute and relative numbers in reported injecting in recent years. A similar trend of declining injecting has been described in the Netherlands [27] but is in contrast to North America, where injecting opiates (and HCV infections) has increased during the past decade [28, 29] . This emphasizes that continuous testing and surveillance is important, as drug use patterns will change over time. Several countries have reported the injection of central stimulants as an emerging problem [30, 31] . Injecting cocaine use is a major risk for HCV spread and 32% of PWID in this cohort had disclosed stimulant injecting. However, we did not find high exposure to HCV in 'non-OST injectors'.
We found a low number of people exposed to the chronic rate (55.9%) for HCV infection [16] . A review on the spontaneous clearance rate of HCVat 12 months found it to be 36% (95% CI = 23.5-50.9%), but with a wide variability, and the one included study (n = 57) with PWID only found a clearance rate of 42.1% [32] . In both crosssectional and longitudinal studies the possibility of classifying incident infections as chronic are present, although is more likely in cross-sectional studies in high-incidence populations. Treatment uptake for hepatitis C was very low (< 5%) in Denmark prior to the introduction of DAAs in 2014, but some might have accessed treatment affecting the chronic/exposed ratio.
In the context of reducing transmission of HCV by increasing access to HCV treatment and prevention, the time from when risk behaviour starts to the connection to drug use treatment/OST and to the first test for infection is important. In this cohort, the median time from when injecting started to first HCV test was 6.5 years (IQR = 2.3-13.6), and this is an important challenge to address. A similar problem is the lack of regular testing for those in care. Although the testing lag was substantial, the median age (39 years) at diagnosis of chronic HCV infection in this study was 10 years younger than reported cases at national level in 2017, probably reflecting the reporting lag, as the physician-reporting of chronic HCV infection in Denmark has a known low coverage (40-50%) [33] .
A recent mathematical model on treatment as prevention in Denmark showed that reducing prevalence among PWID to 5% in 15 years was possible if HCV treatment were to be delivered in OST programmes [34] . From a treatment-as-prevention perspective, it is encouraging that 69% of those with known chronic HCV infection are still in care, and should be within reach for HCV treatment in outreach clinics. This might, however, be jeopardized by the low level of surveillance in the youngest and most recent entrants.
In conclusion, we found the population in treatment to consist of two quite different groups, both with regard to test uptake and to HCV prevalence. Although limited by the regional design, we find it fair to conclude that with OST being the strongest determinant for test, future efforts to ensure and encourage testing outside OST is important, especially in the young. Furthermore, the majority of HCVinfected individuals were still in drug treatment, illustrating the importance of integrating hepatitis care into this setting in future. Furthermore, declining injecting drug use and HCV prevalence cohorts suggest favourable conditions for hepatitis C elimination in our setting. However, this will require increased testing within and beyond drug treatment facilities.
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